



## **NeuroEM Therapeutics Announces Addition of Two New Members to its Board of Directors**

Phoenix, AZ (March 29<sup>th</sup>, 2019) NeuroEM Therapeutics, a clinical-stage medical device company targeting Alzheimer's Disease, has just announce that two new members have joined its Board of Directors. The company is clinically testing a novel bioengineering technology called Transcranial Electromagnetic Treatment (or TEMT) to stop or reverse Alzheimer's memory impairment.

The two new members are Dr. Edward Goodwin of Stratford, Connecticut and Mr. Michael St. Lawrence of Boston, Massachusetts. "We are most pleased to welcome Ed and Michael to NeuroEM as board members since they both offer excellent backgrounds and experience that will provide critical guidance for NeuroEM as it continues its clinical testing of TEMT as a promising new technology against Alzheimer's Disease" said Dr. Gary Arendash, NeuroEM's Founder and CEO.

Dr. Goodwin was a molecular biologist at Yale University and past president of the Angel Investor Forum (AIF), Connecticut's largest group of angel investors that provided significant early support to NeuroEM. He also served as the Chief Technical Officer for pharma and medical device startup companies and is an investor in NeuroEM. "I am very excited to help shepherd TEMT from Gary's visionary work into advanced human trials with the goal of providing relief to those suffering from this devastating disease" said Dr. Goodwin.

Mr. St. Lawrence is a strategic adviser for The Glass Charitable Foundation. The Foundation provided all funds necessary to perform and complete NeuroEM's Phase I clinical trial in Alzheimer's subjects. Mr. St. Lawrence was Director of Business Development at Rogers Corporation prior to his current position as Principle Director at Argyle Enterprises, which implements investments in high potential, early stage companies. "I'm glad to be a part of NeuroEM's groundbreaking efforts to address the growing Alzheimer's Disease epidemic." said Mr. St. Lawrence.

Both of these individuals had been instrumental as advisors in guiding the company over the past two years prior to accepting their Board of Director positions. "With the rapid progress made by NeuroEM, we anticipate expanding NeuroEM's Board of Directors further within the next year" said Dr. Arendash. "Especially with completion of NeuroEM's Phase I clinical trial a few months ago, this is now an exciting and critical time for the company – a time when it is essential to have board members with the business/scientific acumen and passion that both Ed and Michael have."

NeuroEM is clinically developing a novel head device, worn daily in-home for an hour or two, that provides global electromagnetic treatment to the human brain. The company has strong pre-clinical data suggesting that TEMT has multiple disease-modifying mechanisms of action against Alzheimer's.

Approximately six million Americans have Alzheimer's Disease. There is currently no effective preventative or treatment for this disease that ravages the memory of those affected and puts a tremendous psychological burden on caregivers. The total cost associated with Alzheimer's Disease in the U.S. is currently over a quarter of a trillion dollars per year.

## **About NeuroEM Therapeutics, Inc.**

NeuroEM Therapeutics is a clinical stage medical device company focused on development of Transcranial Electromagnetic Treatment (TEMT) to treat neurodegenerative disorders such as Alzheimer's Disease, Traumatic Brain Injury, and Down's Syndrome. The company is headquartered in Phoenix, AZ and has attained research support from NIH, foundations, and angel investors. NeuroEM's head device (the MemorEM 1000) is a first-in-class medical device that provides full brain electromagnetic treatment in-home and with near complete mobility. For more information about NeuroEM Therapeutics, go to [www.neuroem.com](http://www.neuroem.com).

## **Forward-Looking Statements**

This communication contains certain forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of NeuroEM Therapeutics, are based on management's current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements.